寡转移性前列腺癌转移导向治疗的生物学与临床依据
本文综述了寡转移性激素敏感性前列腺癌初始管理的快速进展,包括两项随机对照试验亚组分析提示同步寡转移状态可能预测原发灶放疗获益,以及三项II期试验支持转移导向治疗。文章将前列腺癌自然史整合为模型,认为转移性前列腺癌的总疾病活动度主要由疾病负荷与基因组不稳定性等生物学因素共同驱动,并强调需临床试验参与以推进患者照护。
要点
- 两项随机对照试验亚组分析提示同步寡转移前列腺癌可能从原发灶放疗中获益。
- 三项II期临床试验支持在不同前列腺癌人群中探索转移导向治疗。
- 提出总疾病活动度由疾病负荷与基因组不稳定性共同驱动的假说。
核心结论
- 转移性前列腺癌的总疾病活动度主要驱动因素是疾病负荷与基因组不稳定性等生物学特征的组合。
研究设计与样本
- 本文为综述,整合前列腺癌自然史理解并构建模型,未报告系统检索范围。
主要发现
- 两项随机对照试验的亚组分析提示特定同步寡转移性前列腺癌状态可能预测原发灶放疗获益。
- 三项II期临床试验支持在不同前列腺癌人群中进一步探索转移导向治疗。
- 应用现有证据存在诸多注意事项,当前和即将开展的临床试验正在解决这一困境。
临床怎么用
- 临床应认识到现有证据存在注意事项与临床均势,需通过临床试验参与来适当推进患者照护。
局限性
- 现有证据存在诸多注意事项,且所提出的假说仍有许多未解问题挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The initial management of potentially oligometastatic hormone sensitive prostate cancer has been complicated by rapid advances in the field. Clinically, subgroup analyses of two randomized control trials have suggested that a specific synchronous oligometastatic prostate cancer state may be predictive for benefit from radiation to the primary. Further exploration of metastasis-directed therapy has been supported for various prostate cancer populations among three phase II clinical trials. There are numerous caveats in applying this evidence, a dilemma being addressed by present and upcoming clinical trials. Despite existing clinical equipoise and an avenue to address this uncertainty, the temptation to combine this evidence off-trial exists. Matters have become more complex as our ability to evaluate metastatic disease and tumour biology have also matured. This paper synthesizes our understanding of prostate cancer's natural history into a model which rationalizes both the theoretical benefits and limitations of metastasis directed therapy. We postulate that a metastatic prostate cancer's total disease activity is primarily driven by the combination of its burden of disease and underlying biology, namely genomic instability, then highlight the numerous remaining questions that challenge this hypothesis. This review focuses on harmonizing the language used to describe the disease, the current efforts exploring this hypothesis, and the need for clinical trial participation to appropriately advance patient care.
引用
- Kucharczyk MJ, So J, Gravis G, et al. A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. Radiother Oncol. 2020. PMID: 32858066. doi:10.1016/j.radonc.2020.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。